GLP-1 Weight Loss Requires Muscle, Protein, and Strength Training

The most useful distinction in this discussion is not between “natural” health practices and biohacking. It is between interventions that build physical capacity, tests that clarify a decision, and experimental treatments whose benefits, risks, access, and evidence remain contested.

Gabrielle Lyon repeatedly returned to the first category: muscle, strength, bone, sufficient protein, and the ability to remain physically capable through aging. Ben Greenfield made a similar case from the cardiovascular side, emphasizing resistance training, short bouts of intense activity, and walking pace. Neither treated advanced interventions as substitutes for those foundations.

At the other end of the spectrum were peptides, stem-cell products, plasmapheresis, and gene-related treatments. Brigham Buhler argued that patients should have greater supervised access to such tools, particularly when conventional medicine offers little. Lyon agreed that unmet needs push people toward experimental care, while maintaining that broader medical acceptance will require stronger trials and reliable product quality.

Between those categories sit diagnostics. The value of a DEXA scan, a cardiovascular scan, hormone measurement, or bloodwork is not that it produces more health data. It is that it can distinguish a genuine problem from a presumed one: plaque from an unfavorable lipid panel, poor muscle quality from low lean mass, symptomatic hormonal dysfunction from a single threshold number.

That hierarchy matters most in the group’s discussion of GLP-1 drugs. They see the medications as a major advance, but one that can create a new failure mode if weight loss becomes the only outcome worth measuring.

Lyon does not regard GLP-1 drugs as a mistake. She sees them as a tool medicine needed after decades of failure to address obesity. But the scale and speed of weight loss they permit, she argued, could shift the central problem toward sarcopeniaLoss of muscle mass and strength associated with frailty.: people becoming thinner without remaining physically robust.

Greenfield put the concern more bluntly: the transition may be “from people who are too big to people who are too frail.”

For Lyon, the issue is not simply that a DEXA scan reports lean-mass loss. She argued that GLP-1s may improve muscle composition by reducing fat within muscle. Her analogy was a Wagyu steak becoming a filet: less intramuscular fat can improve the tissue’s quality even if a conventional measure registers a fall in lean mass. Greenfield added that studies he had seen on retatrutide used DEXA measures that could not distinguish skeletal-muscle loss from reductions in intrahepatic tissue, intramuscular triglycerides, and other tissue whose reduction might be favorable.

That does not remove the practical risk. Greenfield said people taking strongly appetite-suppressing doses can struggle to eat enough to train or consume adequate protein. The resulting muscle loss, in his account, may not be a direct mechanistic consequence of GLP-1 activity. It can follow from low food volume, low energy, poor gym performance, and inadequate protein intake.

Lyon’s position is therefore not anti-GLP-1. She said the drugs are likely here to stay, may improve muscle quality, and may be necessary because previous approaches have been inadequate. Her concern is that body weight cannot be the sole endpoint. Appetite suppression needs to be paired with enough food, protein, resistance training, and attention to bone and muscle if people are not to exchange one form of metabolic risk for another.

Her account of osteoporosis made the same long-term point. “Osteoporosis is a pediatric disease with geriatric outcomes,” she said: what happens during youth helps set the conditions for later bone health. She cited menstrual disruption in underweight athletes, anorexia, and low bone mineral density as examples of how early undernutrition can shape later risk. Muscle and bone, in this account, are not cosmetic reserves. They are part of the capacity to remain mobile and independent.

Buhler argued that the current GLP-1 rollout is not necessarily designed around those trade-offs. In his account, foundational trials and insurance rules were built around chronically ill, morbidly obese patients, originally in the context of diabetes. The resulting prescribing pathways can then be applied to people with different needs: someone trying to lose a relatively small amount of weight may be directed toward doses studied in a much heavier and sicker population because those are the doses insurers recognize.

He described a patient whose insurer stopped covering one tirzepatide dose and sought to move her to a higher covered dose, despite the lower dose already producing the desired result. Buhler presented this as the logic of indication-based medicine: treatment follows trial-approved doses, formularies, and reimbursement arrangements rather than a patient-specific minimum effective dose.

Greenfield used his own occasional flight-day practice to illustrate the gap. He said he has used a 0.25-milligram microdose to quiet food noise when sedentary and without good food options, contrasting it with what he characterized as standard semaglutide-range doses of 8 to 12 milligrams. He did not offer that as a general protocol. His point was that appetite effects may occur well below the doses that dominate formal treatment pathways.

Lyon also said clinical observations and emerging research may point toward other low-dose uses, including inflammation and possibly cancer-related effects. But when Chris Williamson asked whether those observations might simply reflect reduced food intake, Lyon did not claim an answer.

She relayed an inflammation hypothesis, but said the mechanism remains unresolved.

Lyon argued that GLP-1s do more than slow gastric emptying and make food less compelling. Their effects on dopamine and reward pathways, she said, are part of why the drug class is being considered in addiction-related contexts—and may also explain changes patients report in sexual desire, mood, spending, eating, and enjoyment more generally.

She said the emerging pattern appears to differ by sex. In men, fat loss and hormonal changes may increase testosterone and sex drive. In women, Lyon said, GLP-1s may reduce body fat while also reducing libido. The evidence is still emerging, she added, because widespread use has not been long enough to map every secondary outcome.

Williamson widened the question beyond clinical practice. Consumer life is driven by repeated desire: food, sex, purchases, games, pornography, social media, intoxicants. If GLP-1s suppress hedonic drive, he asked, what happens when that effect becomes widespread? Greenfield’s joke—“GLP to GDP”—carried the underlying proposition: a drug that dampens appetite may also alter the desire patterns on which many habits and markets rely.

Lyon’s clinical version of the concern was more immediate. She said some patients become “a little depressed” and no longer derive the same enjoyment from sex, food, or spending. That was not, in her view, a reason to reject GLP-1 prescribing. It was a reason not to treat weight reduction as the whole outcome.

The comparison raised in the discussion was bariatric surgery. Williamson argued that people who use food to manage distress may lose access to an established reward and sedation pathway without resolving the underlying problem. GLP-1 treatment could present a similar problem: weight loss may work while trauma, low mood, compulsive behavior, or the conditions that drove overeating remain.

Buhler’s criticism focused on the setting in which the medication is delivered. In an insurance-driven primary-care practice, he said, a clinician may have only minutes with a patient who is prediabetic, has weight to lose, and asks for a GLP-1. The prescription can produce an immediate win while broader questions—hormonal status, family history of depression or anxiety, diet, training capacity, and the causes of weight gain—receive less attention.

Lyon agreed that a full workup matters, but rejected the idea that medication must always wait until every root cause has been fixed. Her analogy was thyroid replacement or glasses. Restoring a deficient function is not normally treated as moral failure or a shortcut. In her view, hormone treatment should be understood similarly when a person has a genuine deficiency.

The group treated testosterone as a case study in the way medicine and culture collapse distinct questions into one. A person with symptomatic hypogonadism and a person taking supraphysiological doses for athletic performance are not pursuing the same intervention, but public language often treats both as “steroids” or “juicing.”

Gabrielle Lyon argued that low testosterone is associated with medical risks involving heart disease, osteoporosis, cognition, and depression. The clinical task, as she sees it, is not to make everyone more muscular or aggressive. It is to recognize deficiency and restore physiological function where appropriate.

Lyon and Buhler traced part of testosterone’s stigma to an older prostate-cancer interpretation associated with Huggins. They said the original study involved three patients and helped establish a durable medical dogma that suppressing androgens was protective. They also said later work by urologist Abraham Morgentaler challenged the proposition that testosterone itself causes prostate cancer or necessarily worsens cardiovascular disease.

Their case was not that testosterone is free of complications. Ben Greenfield named excess conversion to estrogen, with possible emotional changes or gynecomastia, and increased conversion to DHT, which can contribute to male-pattern hair loss. Buhler said those issues are more likely when treatment moves beyond physiological ranges. Their shared point was that these are not the same as the older claim that normal-range replacement inevitably drives life-threatening disease.

Lyon’s strongest example involved military screening. She said the proposal under discussion is not to pharmacologically enhance every soldier; it is to identify personnel with low testosterone who may be entering demanding conditions at a disadvantage. She argued that service members are not routinely screened and said women should also be included, though hormonal assessment is more complex.

Williamson pressed on whether the threshold for “low” testosterone is itself too low. Lyon said the U.S. lower boundary is generally treated as 300 nanograms per deciliter, although thresholds vary across countries. In her opinion, that number is too low, but she stressed that a number alone cannot settle the question.

She described a Homeland Security officer with a testosterone level of 600 who nevertheless showed signs and symptoms associated with low testosterone. Lyon said he had a CAG repeat affecting receptor function: testosterone was present but not signaling effectively. A total testosterone level of 900 in one person, she argued, may not function equivalently to 300 in another. Such receptor characteristics are not routinely tested in standard clinical practice.

This is where the case for personalized care becomes concrete. Greenfield noted that an insurer may cover a patient at 299 but not at 301, even if the clinical picture is otherwise nearly identical. Buhler argued that this is the limitation of a system organized around categorical eligibility rather than symptoms, receptor function, and individual physiology.

Greenfield took the most qualified position on treatment sequence. Testosterone replacement is not, he said, the first answer for everyone. Resistance training, sleep, recovery, relationships, sunlight, stress reduction, adequate nutrition, and micronutrients should be considered. He named creatine, zinc, boron, omega-3s, and magnesium as upstream supports worth addressing.

But he also argued that modern life can make those measures insufficient. Endocrine disruptors, plastic exposure, personal-care products, industrial pollution, light pollution, stress, sedentary work, and less physical labor may all contribute to lower testosterone availability. Lyon pushed back on treating ideal lifestyle conditions as a prerequisite for care. A warfighter, a new mother, or anyone under severe constraints may not be able to sleep more, regulate light exposure, eat perfectly, or reduce stress before receiving treatment.

Greenfield’s own account was experiential. He said he began testosterone at 40 and, after four years, views it as increasingly important with age because it improved recovery and allowed him to sustain frequent training with less soreness and better HRV. He also emphasized fertility. Younger men considering testosterone, he said, need to understand its potential effect on sperm production and work with a practitioner who can discuss preservation and maintenance strategies.

Lyon agreed. Banking sperm and using interventions such as HCG where appropriate, she said, can allow treatment without treating fertility as an afterthought. Her concern is that fear of the word “steroids” can prevent people from addressing genuine deficiency.

Brigham Buhler framed the dispute over peptide compounding around a distinction he returned to repeatedly: safety, efficacy, and insurance coverage are different questions.

Buhler said that, during the Biden administration, the FDA placed 17 peptides on what he called a “naughty list,” characterizing them as too risky to compound. In his account, the change arrived with little warning and without public adverse-event data that explained the decision. Compounding pharmacies could no longer legally make products that he said had been available for years. Demand did not disappear; it moved toward gray- and black-market sellers.

He pointed to a Florida peptide manufacturer that he said had been federally indicted after sourcing active pharmaceutical ingredients from China that were contaminated with testosterone. In the scenario he described, women injecting what they believed were peptides could unknowingly receive testosterone. His argument was that closing a regulated path without addressing persistent demand makes adulterated products more likely to fill the gap.

Buhler said his group submitted more than 800 studies and 5,000 pages of material to an FDA hearing. That included a retrospective analysis of 16 million BPC-157 patients which, he said, found three adverse events. He emphasized that the hearing was about safety rather than efficacy: the question was whether a cash-paying patient, under clinical supervision and with a prescription, could obtain a compounded product from a regulated pharmacy—not whether every peptide should become an insurer-funded approved drug.

He also objected to what he described as an uneven process. Reviewing clinicians, he said, received little time to assess submitted materials, while an FDA public statement relied on a dataset from a black-market manufacturer rather than a compounding pharmacy. Buhler said clinicians voted to overturn restrictions on six of seven peptides considered, while FDA representatives voted in the other direction.

His broader argument is that the new-drug-indication system favors compounds that can be patented and defended commercially. The clinical evidence regulators demand can be expensive to generate; a molecule readily available in nature may not offer the exclusivity needed to finance that process. He described compounding as an older apothecary tradition intended to provide patient-specific access, rather than a loophole that exists only at the discretion of pharmaceutical manufacturers.

Gabrielle Lyon did not reject the demand for better trials. Randomized controlled trials, she said, are valuable, and the wider medical community will need them to accept peptide treatments. But she also said conventional care leaves needs unmet, which is why patients seek peptides, plasmapheresis, and other alternatives before the research base is complete.

The sharpest unresolved problem is product integrity. Lyon defended patient agency, including the right of someone with five pounds to lose to seek a medication if they choose. But she also asked how a patient can know that a pharmacy is ethical and that the product received is the product represented. Freedom of access does not protect people who believe they are buying one compound and receive another.

Buhler’s answer is a clinician-supervised right-to-try model, particularly for people with terminal, progressive, or catastrophic disease. He cited Brett Favre’s Parkinson’s disease as an example of someone for whom conventional medicine may have little to offer while experimental approaches might, in his view, slow decline or improve quality of life. If a patient has reached the end of established options, Buhler argued, they should be able to take informed risks with their own money under medical supervision.

Buhler identified Muse cells as the intervention he considers most important. He described them as a subset of stem cells discovered by Mari Dezawa in Japan, with “Muse” standing for multi-lineage stress enduring.

According to Buhler, fewer than 2% of stem cells are Muse cells, but they can remain alive at room temperature for days, may cross the blood-brain barrier, engraft more quickly and at a higher rate than conventional mesenchymal stem cells, and take on the phenotype of damaged tissue. He contrasted them with cells from bone marrow or fat tissue, which he said have more fixed phenotypes and frequently become trapped in the lungs.

Buhler cited Japanese work involving stroke patients and children with encephalitis, as well as a patient at his clinic whom he said was removed from a heart-transplant list after intravenous treatment. He also described Muse cells as potentially relevant to tendon, joint, orthopedic, heart, and neurological conditions. The cells, he said, are sourced from healthy births through planned C-sections, using discarded afterbirth tissue.

He also stressed that Muse-cell use is not FDA-approved for any indication and that availability varies by state. The tension is built into the claim: he sees an unusually promising intervention, while acknowledging that it remains experimental and legally uneven.

Plasmapheresis belongs to a more established medical category but is being assigned broader longevity ambitions. Lyon said it remains a hospital procedure for serious conditions in which antibodies or other problematic substances are concentrated in plasma. Greenfield described the elective version as drawing blood, filtering plasma, and replacing the removed volume—typically with albumin, sometimes with plasma or additional products.

Ben Greenfield called it an “oil change” for the body and described elective filtration protocols aimed at microplastics, lipid management, mold exposure, and chronic inflammation. Buhler cited a trial that he said found an 18-month reduction in biological age among people over 50. He also described Jelly Roll reporting improved sleep after plasmapheresis during a period of major weight loss and persistent inflammation.

They did not describe the procedure as consequence-free. Buhler said plasma removal compromises immune function for roughly 24 hours and advised against flying immediately afterward. Greenfield added that catheter placement carries its own risks. Albumin is used to replace volume during the procedure; Buhler called it a protein placeholder.

The discussion reached an even more experimental edge with gene-related intervention. Greenfield said he received a follistatin-related treatment in Roatán and gained around 10 pounds of muscle in three months without changing calories, protein intake, or training protocol. He said the effect was not permanent and might require repeating every year to 18 months.

The more consequential issue for Greenfield was reversibility. He said he initially understood the treatment to be reversible and later learned it was not. Buhler distinguished the intervention from CRISPR editing: as he understood it, the technology upregulates or downregulates an existing gene rather than cutting DNA. Greenfield accepted that distinction while maintaining that he would want a way to reverse an intervention if something went wrong.

When asked for cost-free longevity interventions, Greenfield did not name peptides, filtration, cold exposure, or specialized devices. He named physical capacity: lifting and carrying, cardiorespiratory fitness, and walking pace.

Grip strength matters, he said, not because squeezing a hand dynamometer is inherently a life-extension strategy. It matters because strong grip often reflects the lifting, carrying, manual labor, and gym training that built it. VO2 max is similarly useful less as a number to chase than as a broad reflection of cardiovascular function.

Greenfield said brief bursts of exertion can matter. He referred to a study that, in his account, found that 10-to-20-second efforts done three to five times weekly improved VO2 max. His example was a short Airdyne sprint rather than a formal Norwegian 4x4 interval protocol.

Asked to choose between muscle mass and VO2 max, Greenfield chose muscle. His rationale was frailty: a person is more likely to be harmed by an ordinary fall or failure to recover from a misstep than by an inability to outrun a predator. Strength training, he said, can also support cardiovascular health and blood-pressure management. The choice is artificial, he added; people need both.

Lyon preferred “healthspan” or “muscle span” to longevity. Aging is normal, she said. Chronic disease should not simply be accepted as normal aging. The relevant aim is to remain strong, capable, and functional over the years available—not to treat every intervention as an attempt to evade death.

That view also shaped her objections to extended protein restriction. She relayed discussions from a Protein Working Group summit, saying participants did not agree on every threshold but did agree there was no evidence of benefit from going below minimum protein requirements. Lyon described a likely human “sweet spot” for aging and optimal health of roughly 1.2 to 1.6 grams per kilogram, while acknowledging that requirements vary with age, activity, and anabolic demand.

Greenfield gave his teenage sons as an obvious counterexample to a universal target: they train twice daily and lift regularly, and may eat 1.4 to 1.5 grams per pound. Lyon’s concern was particularly directed at older adults. The body turns over an estimated 250 to 300 grams of protein daily, she said, and becomes less efficient at doing so with age. In her account, human aging data do not support sustained protein restriction as a strategy for older people.

Buhler’s argument for prioritizing protein was less technical. He finds it filling and nutrient-dense, leaving less room for ultra-processed food. A steak, he said, ends an eating episode for him; protein is difficult for him to calorically overconsume.

Fiber received a more conditional treatment than protein. Greenfield said it can support glycemic stability, bowel movements, the microbiome, and postbiotic production. But blanket high-fiber advice can be a problem for someone with small intestinal bacterial overgrowth, diverticulitis, IBS, particular gas-producing bacteria, or sensitivity to fermentable fibers such as inulin and chicory root.

A large kale salad or spinach-heavy smoothie can help one person and create severe symptoms for another, Greenfield said. The question is not whether fiber is good or bad in the abstract. It is the type, dose, fermentability, and the person’s response.

Lyon said the food-matrix question is likely the next frontier. A steak is not only protein; it also contains B vitamins, anserine, taurine, and other compounds. Dairy contains fats, proteins, and carbohydrates that may act differently together than as isolated supplements. Foods, in her view, should not be reduced entirely to macros.

The practical advice from the group was modest. If higher fiber brings gas and bloating, simplify rather than add more products. Lyon favors stool and breath testing when she suspects SIBO. Greenfield suggested a lower-cost at-home breath device or a conventional elimination diet: reduce the diet to a manageable base, then add grains, dairy, and different fibers back over several weeks.

Greenfield applied the same logic to cardiovascular testing. Lipid panels and cardiovascular risk scores, he argued, are clues rather than direct evidence of coronary plaque. LDL, HDL, triglycerides, Lp(a), ApoB, blood pressure, family history, and smoking history can inform risk, but they do not show plaque itself.

He favors CT coronary angiography with AI-based image analysis, including Cleerly scans, because it can identify calcified and softer plaque. In his view, someone can have a favorable lipid panel and still have meaningful plaque deposition, while another may be taking lipid-lowering medication without evidence of plaque. Imaging can make the clinical picture more specific than a lipid panel alone.

Lyon agreed that men often miss opportunities for early baselines after leaving pediatric care. She said her practice recommends a baseline heart scan by 40, including both hard and soft plaque. The group estimated an out-of-pocket cost of around $1,000.

They also acknowledged limits. Greenfield said radiation exposure varies by scanner, imaging software changes over time, and a scan processed under one generation of software may not be directly comparable with one processed years later. Imaging can also reveal abnormalities that frighten people without requiring intervention. His own full-body imaging, he said, shows extensive spinal arthritis despite his being largely pain-free and active.

Lyon would extend the imaging logic to muscle. DEXA separates bone, fat, and estimated lean mass but does not routinely assess muscle quality or intramuscular fat. She expects MRI, ultrasound, or other methods of assessing muscle quality to become more important in understanding insulin resistance and disease risk.

The common principle is that a test earns its cost when it changes the decision. A number by itself can become another source of distraction; a result that clarifies whether to train differently, investigate further, monitor a condition, or use medication belongs in a different category.

The most concrete environmental-health point was not that every possible exposure has a known health effect. It was that measuring an environment and changing it are separate tasks.

Williamson argued that an air-quality sensor placed inside a purifier or scrubber may not represent the air elsewhere in a room because that device is processing air at a high turnover rate. In his formulation, one device should measure the environment; another should change it.

Ben Greenfield described what he considers an ideal indoor-air setup as three distinct functions: particulate filtration, limiting mold buildup in ducts, and bringing fresh outdoor air inside rather than merely cleaning stale air. A filter catches particles; a scrubber can limit accumulation in ducts; and a recirculation system exchanges indoor and outdoor air.

Greenfield said he uses standalone HEPA filters in the kitchen because ordinary stove hoods may not capture all particulate matter released during cooking. He also uses them during wildfire smoke and travel. Lyon said her household uses multiple air filters as well.

Mold was the related issue Lyon expects to become more prominent. Her practice treats mold and environmental toxins, and she emphasized individual variation. There is no formula, she said, that turns a given duration of exposure into a predictable illness, but even a week can affect some people. Williamson described becoming seriously ill in a moldy home while a roommate living in the same environment appeared unaffected.

The microplastics exchange supplied a caution about measurement rather than a settled conclusion about every exposure source. Williamson showed an item about a University of Michigan study reporting that nitrile and latex gloves can release particles called stearates that resemble microplastics and contaminate samples, at times inflating apparent pollution estimates. The point was not that plastic exposure is irrelevant. It was that an alarming measurement can be compromised by the materials used to collect it.

Greenfield said research he had seen identified oral exposure from food packaging and storage as the largest contributor to microplastic exposure. Lyon emphasized how difficult that exposure is to eliminate when so much food is sold in plastic. Their practical focus was narrower: avoid heating food in plastic when possible and avoid hot drinks in foam cups.